Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 157 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Adaptive Radiotherapy Clear all
Active, not recruiting Not applicable Interventional

Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer

NCT03621644
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Stereotactic MRI-guided On-table Adaptive Radiation Therapy
Radiation
Lead sponsor
Viewray Inc.
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Miami, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 3, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

NCT00809991
View directory record Official record
Conditions
Prostate Cancer
Interventions
hypofractionation
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 3, 2026, 2:15 PM EDT
Recruiting No phase listed Observational

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

NCT06904365
View directory record Official record
Conditions
Uterine Cancer, Rectal Cancer, Colon Cancer, Breast Cancer, Lung Cancer, Sarcoma, Cervix Cancer, Head and Neck Cancer, Anal Cancer, Liver Cancer, Gastric Cancer, Bladder Cancer
Interventions
HyperSight cone beam computed tomography (CBCT) scan, ETHOS 2.0
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 3, 2026, 2:15 PM EDT
Active, not recruiting Phase 2 Interventional

Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy for Metastatic Cervical Cancer

NCT05021237
View directory record Official record
Conditions
Stage IV Cervical Cancer FIGO 2018, Adenosquamous Carcinoma of Cervix, Cervical Cancer, Metastasis
Interventions
Ultra-fractionated radiation therapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 3, 2026, 2:15 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

NCT02492867
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Response-driven Adaptive Radiation Therapy, Carboplatin, Paclitaxel, FDG-PET, V/Q SPECT, Durvalumab
Radiation · Drug · Device
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 3, 2026, 2:15 PM EDT
Active, not recruiting Early Phase 1 Interventional

Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

NCT05108428
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Capecitabine, Radiation Therapy, FOLFOX regimen
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 3, 2026, 2:15 PM EDT
Terminated Early Phase 1 Interventional

4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy

NCT01034514
View directory record Official record
Conditions
Lung Cancer
Interventions
Real-time Position Management system, Discovery ST multislice PET/CT scanner, Infinia Hawkeye SPECT/CT gamma camera, Pinnacle3 treatment planning system, SKYLight nuclear camera, DTPA, TECHNETIUM TC 99M MAA
Device · Drug
Lead sponsor
Billy W. Loo Jr.
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 7, 2017 · Synced Sep 3, 2026, 2:15 PM EDT
Withdrawn Not applicable Interventional

Feasibility of Adaptive Radiation Therapy for Human-papilloma Virus-positive Oropharyngeal Cancer Patients on MRIdian Linac

NCT05849142
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
MRIdian Linac
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 3, 2026, 2:15 PM EDT
Recruiting Early Phase 1 Interventional

Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

NCT05996432
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Brain Metastases
Interventions
Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), 18F-fluoromisonidazole
Procedure · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Sep 3, 2026, 2:15 PM EDT
Completed Not applicable Interventional

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

NCT06004167
View directory record Official record
Conditions
Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma, Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
Interventions
Adaptive Bridging Radiation Therapy (ABRT)
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 3, 2026, 2:15 PM EDT
Terminated Phase 2Phase 3 Interventional

A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)

NCT06295809
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Skin Neoplasms
Interventions
Pembrolizumab, Intismeran autogene, Surgery
Biological · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Los Angeles, California • Newport Beach, California • Palo Alto, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 3, 2026, 2:15 PM EDT
Terminated Phase 2 Interventional Results available

Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer

NCT04162665
View directory record Official record
Conditions
Gastric Adenocarcinoma
Interventions
Adaptive short course radiation therapy, Standard of care chemotherapy regimen
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 3, 2026, 2:15 PM EDT
Active, not recruiting Phase 2 Interventional

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

NCT04331041
View directory record Official record
Conditions
Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma
Interventions
Adaptive stereotactic body radiation therapy, Defactinib, Tumor biopsy, Research blood draw
Device · Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 3, 2026, 2:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

NCT04789486
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
Interventions
AGuIX, Radiotherapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 3, 2026, 2:15 PM EDT
Completed Not applicable Interventional Results available

Image-Guided Adaptive Radiotherapy for in Detecting Tumors During Treatment in Patients With Head and Neck Cancer

NCT01843673
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
computed tomography, cone-beam computed tomography, radiography, electronic portal imaging, image-guided adaptive radiation therapy
Procedure · Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 3, 2026, 2:15 PM EDT
Terminated No phase listed Observational

Image-guided Adaptive Radiotherapy for Cervix Cancer: Patient Image Acquisition

NCT00571415
View directory record Official record
Conditions
Cervix Cancer
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 31, 2016 · Synced Sep 3, 2026, 2:15 PM EDT
Not yet recruiting Early Phase 1 Interventional

Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery

NCT07674771
View directory record Official record
Conditions
Prostate Cancer, Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer, Adaptive Radiotherapy
Interventions
Drug: 68-Ga PSMA11, Adaptive stereotactic ablative radiotherapy (SABR), 68Ga-PSMA-11, Adaptive stereotactive ablative radiotherapy (SABR)
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 3, 2026, 2:15 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
Drug · Radiation · Biological
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 3, 2026, 2:15 PM EDT
Recruiting Phase 2 Interventional

Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial

NCT06444269
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiomics on MRI, microbubble CEUS Contrast Enhanced Ultrasound (CEUS)
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 3, 2026, 2:15 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.

NCT05946824
View directory record Official record
Conditions
Recurrent Prostate Cancer After Surgery
Interventions
Daily-adaptive Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 3, 2026, 2:15 PM EDT
Terminated No phase listed Observational

Assessment of 3D Transperineal Ultrasound Imaging w/ Matrix Array Transducers in Prostate Radiotherapy

NCT02432820
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 3, 2026, 2:15 PM EDT
Completed No phase listed Observational

Pilot Investigation of Dual Energy CT Imaging on an Online Adaptive Radiation Therapy System

NCT07219134
View directory record Official record
Conditions
Genitourinary System Carcinoma, Malignant Pelvic Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 3, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

NCT03335540
View directory record Official record
Conditions
Advanced Cancer
Interventions
Nivolumab, Relatlimab, Cabiralizumab, Ipilimumab, IDO1 Inhibitor, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Sep 3, 2026, 2:15 PM EDT
Withdrawn Not applicable Interventional

Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer

NCT05488626
View directory record Official record
Conditions
Stage III Non-small Cell Lung Cancer
Interventions
Adaptive Radiotherapy, Non-Adaptive Radiotherapy, Chemotherapy, Immunotherapy
Device · Drug
Lead sponsor
Varian, a Siemens Healthineers Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 3, 2026, 2:15 PM EDT